- Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis (AS), also known as radiographic axSpA, and nr-axSpA - INDIANAPOLIS , June 1, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S.

- First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly's collaboration with AbCellera   - The placebo-controlled study will assess safety and tolerability in patients hospitalized with COVID-19 with results anticipated by the end of June   - Should Phase 1

CYRAMZA, in combination with erlotinib, now approved for the treatment of people with untreated metastatic non-small cell lung cancer (NSCLC) with certain activating EGFR mutations, based on the positive global Phase 3 RELAY study   CYRAMZA regimen reduced the risk of disease progression or death

The first and only approved diagnostic agent to image tau neurofibrillary tangles in the brain INDIANAPOLIS , May 28, 2020 /PRNewswire/ -- TAUVID ™ , a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and

INDIANAPOLIS , May 26, 2020 /PRNewswire/ -- President Donald J. Trump and Seema Verma , Administrator for the Centers for Medicare & Medicaid Services , today announced details of the new Part D Senior Savings Model that will allow people in the Medicare Part D program to buy their monthly

- Ischemic heart disease, including myocardial infarction, is the leading cause of death in the U.S. - EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetes - The trial is part

INDIANAPOLIS , May 26, 2020 /PRNewswire/ -- Emgality ® (galcanezumab-gnlm) significantly improved work productivity and reduced interictal burden, defined as health and well-being between migraine attacks, in an analysis of the 3-month double-blind period of the CONQUER study, which included

Early Alzheimer's disease poses financial burdens on patients, caregivers and society INDIANAPOLIS , May 19, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive impairment (MCI), mild

Latest Phase 1/2 LIBRETTO-001 registrational trial data examining Retevmo™ (selpercatinib) demonstrate commitment to advancing precision medicines for hard-to-treat tumor types Data on Verzenio® (abemaciclib) continue to reinforce the therapy's role in treating people with aggressive HR+, HER2-

- Approved for metastatic RET fusion-positive NSCLC, advanced or metastatic RET-mutant MTC and advanced or metastatic RET fusion-positive thyroid cancer - Accelerated approval based on data from LIBRETTO-001 Phase 1/2, largest trial ever reported in patients with RET-driven cancers - Registrational